Average Ratings 0 Ratings

Total
ease
features
design
support

No User Reviews. Be the first to provide a review:

Write a Review

Average Ratings 0 Ratings

Total
ease
features
design
support

No User Reviews. Be the first to provide a review:

Write a Review

Description

AI plays a crucial role in identifying early-stage cancers, facilitating prompt interventions that enhance survival prospects. Cancer's intricate nature means that each type carries distinct characteristics, packed with extensive data that requires thorough analysis. This is where AI excels, leveraging its capabilities to process complex information, ultimately revealing insights that can significantly aid in cancer treatment strategies. Equipped with precise and relevant data, we take proactive steps in our battle against cancer. By utilizing AI, we are poised to make substantial strides in overcoming this disease. Our AI technology is designed to detect early-stage cancer with remarkable accuracy, achieving detection rates between 97-99%. It proficiently identifies ten of the most prevalent abnormalities found in chest x-rays, thus enhancing one of the most fundamental diagnostic tools. This innovation not only streamlines the radiology workflow but also alleviates the workload for radiologists. Lunit INSIGHT CXR successfully encompasses a wide range of findings, ensuring that we are prepared to tackle the challenges presented by cancer detection and treatment. The future of cancer care looks promising with AI at the forefront of these advancements.

Description

Developed by healthcare professionals for their peers, this technology aims to significantly enhance the quality of life for patients. Our AI-driven platform emphasizes speed, scalability, and security while offering the flexibility and customization that each hospital requires. It serves as a dependable long-term resolution. With RapidAI's stroke portfolio, you can expedite triage and transfer decisions with greater precision. Additionally, it facilitates the swift identification, monitoring, and proactive management of aneurysms. RapidAI's comprehensive suite of products for pulmonary embolism care enables quick detection of suspected PE cases. The AI-enhanced clinical decision support (CDS) software accelerates the decision-making process for physicians; however, it is crucial to recognize that not all AI solutions are equal. Only those CDS tools that possess clinical expertise can accurately identify, locate, characterize, and quantify suspected conditions. This advanced level of precision in AI-powered CDS modules contributes to improved triage and transfer decisions, ultimately leading to enhanced diagnostic accuracy and more efficient vascular care. By integrating these cutting-edge tools, healthcare providers can significantly elevate patient outcomes and operational efficiency.

API Access

Has API

API Access

Has API

Screenshots View All

Screenshots View All

Integrations

No details available.

Integrations

No details available.

Pricing Details

No price information available.
Free Trial
Free Version

Pricing Details

Free
Free Trial
Free Version

Deployment

Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook

Deployment

Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook

Customer Support

Business Hours
Live Rep (24/7)
Online Support

Customer Support

Business Hours
Live Rep (24/7)
Online Support

Types of Training

Training Docs
Webinars
Live Training (Online)
In Person

Types of Training

Training Docs
Webinars
Live Training (Online)
In Person

Vendor Details

Company Name

Lunit

Country

United States

Website

www.lunit.io/en

Vendor Details

Company Name

RapidAI

Country

United States

Website

www.rapidai.com

Product Features

Product Features

Alternatives

Alternatives

qCT Reviews

qCT

Qure.ai
Oncora Reviews

Oncora

Oncora Medical
qCT Reviews

qCT

Qure.ai